Close Menu

NEW YORK – Shares of Twist Bioscience rose 12 percent in afternoon trading on the Nasdaq on speculation that the synthetic DNA manufacturer is close to settling a trade secrets lawsuit filed by Agilent Technologies.

The San Francisco-based company's stock opened Thursday trading at $26.83 and the shares rose sharply in mid-afternoon trade to $30.11.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.